Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Dennis D Hedge, Joe D Strain, Jodi R Heins & Debra K Farver. (2008) New advances in the treatment of Clostridium difficile infection (CDI). Therapeutics and Clinical Risk Management 4:5, pages 949-964.
Read now
Read now
Joseph Guiles, Ian Critchley & Xicheng Sun. (2008) New agents for Clostridium difficile-associated disease. Expert Opinion on Investigational Drugs 17:11, pages 1671-1683.
Read now
Read now
David M Rothstein, Christo Shalish, Christopher K Murphy, Andrew Sternlicht & Lee Ann Campbell. (2006) Development potential of rifalazil and other benzoxazinorifamycins. Expert Opinion on Investigational Drugs 15:6, pages 603-623.
Read now
Read now
Michael N Alekshun. (2005) New advances in antibiotic development and discovery. Expert Opinion on Investigational Drugs 14:2, pages 117-134.
Read now
Read now
Marie-Thérèse Labro. (2005) Anti-inflammatory activity of ansamycins. Expert Review of Anti-infective Therapy 3:1, pages 91-103.
Read now
Read now
William M Geisler. (2004) Approaches to the management of uncomplicated genital Chlamydia trachomatis infections. Expert Review of Anti-infective Therapy 2:5, pages 771-785.
Read now
Read now
Peter DO Davies & WW Yew. (2003) Recent developments in the treatment of tuberculosis. Expert Opinion on Investigational Drugs 12:8, pages 1297-1312.
Read now
Read now
Articles from other publishers (34)
Adila Nazli, David L. He, Huacheng Xu, Zhi-Peng Wang & Yun He. (2022) A Comparative Insight on the Newly Emerging Rifamycins: Rifametane,
Rifalazil, TNP-2092 and TNP-2198. Current Medicinal Chemistry 29:16, pages 2846-2862.
Crossref
Crossref
Ichrak Benamri, Ahmed Moussa & Fouzia Radouani. (2019) Genes and mutations involved in the resistance of chlamydia species to antibiotics. Genes and mutations involved in the resistance of chlamydia species to antibiotics.
L. Figueroa-V, F. Diaz-Cedil, E. Garcia-Cer, E. Pool-Gomez, M. Lopez-Ramo, B. Sarabia-Al, M. Rosas-Next & R. Mendoza-Lo. (2013) Antimicrobial Activity Induced by A Steroid-brucine Derivative on S. typhi, K. pneumoniae and E. coli. Journal of Biological Sciences 14:1, pages 67-72.
Crossref
Crossref
Bhuwan B. Mishra & Vinod K. Tiwari. (2011) Natural products: An evolving role in future drug discovery. European Journal of Medicinal Chemistry 46:10, pages 4769-4807.
Crossref
Crossref
Lauro Figueroa-Valverde, Francisco Díaz-Cedillo, Abelardo Camacho-Luis, Maria López Ramos & Elodia Garcia Cervera. (2010) Synthesis of a dihydrotestosterone–ciprofloxacin conjugate: relationship between descriptors logP, π, R m , and V m and its antibacterial activity in S. aureus and E. coli. Monatshefte für Chemie - Chemical Monthly 141:3, pages 373-380.
Crossref
Crossref
Vadim V. Mozhaev, Lyudmila V. Mozhaeva, Peter C. Michels & Yuri L. Khmelnitsky. (2008) Extractive Biotransformation for Production of Metabolites of Poorly Soluble Compounds: Synthesis of 32-Hydroxy-rifalazil. Drug Metabolism and Disposition 36:10, pages 1998-2004.
Crossref
Crossref
David M Rothstein, Robert J Suchland, Minsheng Xia, Christopher K Murphy & Walter E Stamm. (2008) Rifalazil Retains Activity Against Rifampin-resistant Mutants of Chlamydia pneumoniae. The Journal of Antibiotics 61:8, pages 489-495.
Crossref
Crossref
Xicheng Sun, Joseph Guiles & Nebojsa Janjic. 2008.
269
279
.
Marita Larsson & Feng Han. (2007) Determination of rifalazil in dog plasma by liquid–liquid extraction and LC–MS/MS: Quality assessment by incurred sample analysis. Journal of Pharmaceutical and Biomedical Analysis 45:4, pages 616-624.
Crossref
Crossref
Marita Larsson, Arthur F. Michaelis, Yongdong Zhu & Kumar Ramu. (2007) Determination of rifalazil, a potent antibacterial agent, in human plasma by liquid–liquid extraction and LC–MS/MS. Journal of Chromatography B 859:1, pages 103-110.
Crossref
Crossref
Wing Wai YEW & Chi Chiu LEUNG. (2007) Management of multidrug-resistant tuberculosis: Update 2007. Respirology 0:0, pages 071031182005003-???.
Crossref
Crossref
Jing Li, Zhenkun Ma, Katrina Chapo, Dalai Yan, A. Simon Lynch & Charles Z. Ding. (2007) Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins. Bioorganic & Medicinal Chemistry Letters 17:20, pages 5510-5513.
Crossref
Crossref
David M. Rothstein, John van Duzer, Andrew Sternlicht & Steven C. Gilman. (2007) Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections. Archiv der Pharmazie 340:10, pages 517-529.
Crossref
Crossref
Christopher K Murphy, Elena Karginova, Dan Sahm & David M Rothstein. (2007) In Vitro Activity of Novel Rifamycins against Gram-positive Clinical Isolates. The Journal of Antibiotics 60:9, pages 572-576.
Crossref
Crossref
Y.-X. Chen, B. Cabana, N. Kivel & A. Michaelis. (2007) Effect of Food on the Pharmacokinetics of Rifalazil, a Novel Antibacterial, in Healthy Male Volunteers. The Journal of Clinical Pharmacology 47:7, pages 841-849.
Crossref
Crossref
Andrej Trampuz, Christopher K. Murphy, David M. Rothstein, Andreas F. Widmer, Regine Landmann & Werner Zimmerli. (2007)
Efficacy of a Novel Rifamycin Derivative, ABI-0043, against
Staphylococcus aureus
in an Experimental Model of Foreign-Body Infection
. Antimicrobial Agents and Chemotherapy 51:7, pages 2540-2545.
Crossref
Crossref
Philippe Villain-Guillot, Lionel Bastide, Maxime Gualtieri & Jean-Paul Leonetti. (2007) Progress in targeting bacterial transcription. Drug Discovery Today 12:5-6, pages 200-208.
Crossref
Crossref
Z. Ma, A.M. Ginsberg & M. Spigelman. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
699
730
.
David M. Rothstein, Ronald S. Farquhar, Klari Sirokman, Karen L. Sondergaard, Charles Hazlett, Angelia A. Doye, Judith K. Gwathmey, Steve Mullin, John van Duzer & Christopher K. Murphy. (2006)
Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant
Staphylococcus aureus
Isolates in Murine Models of Infection
. Antimicrobial Agents and Chemotherapy 50:11, pages 3658-3664.
Crossref
Crossref
José Barluenga, Fernando Aznar, Ana-Belén García, María-Paz Cabal, Juan J. Palacios & María-Angela Menéndez. (2006) New rifabutin analogs: Synthesis and biological activity against Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters 16:22, pages 5717-5722.
Crossref
Crossref
Marcia S Osburne, Christopher K Murphy & David M Rothstein. (2006) Enhanced Activity of Rifalazil in Combination with Levofloxacin, Linezolid, or Mupirocin against Staphylococcus aureus In Vitro. The Journal of Antibiotics 59:5, pages 303-308.
Crossref
Crossref
Christopher K. Murphy, Steve Mullin, Marcia S. Osburne, John van Duzer, Jim Siedlecki, Xiang Yu, Kathy Kerstein, Michael Cynamon & David M. Rothstein. (2006)
In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant
Staphylococcus aureus
. Antimicrobial Agents and Chemotherapy 50:3, pages 827-834.
Crossref
Crossref
Robert J. Suchland, Kara Brown, David M. Rothstein & Walter E. Stamm. (2006) Rifalazil Pretreatment of Mammalian Cell Cultures Prevents Subsequent Chlamydia Infection. Antimicrobial Agents and Chemotherapy 50:2, pages 439-444.
Crossref
Crossref
Marcia S Osburne, David M Rothstein, Ronnie Farquhar & Christopher K Murphy. (2006) In Vitro Time-kill Activities of Rifalazil, Alone and in Combination with Vancomycin, against Logarithmic and Stationary Cultures of Staphylococcus aureus. The Journal of Antibiotics 59:2, pages 80-85.
Crossref
Crossref
Ying Zhang, Katrin Post-Martens & Steven Denkin. (2006) New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today 11:1-2, pages 21-27.
Crossref
Crossref
M. T. Labro, V. Ollivier & C. Babin-Chevaye. (2005) Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear Neutrophils. Antimicrobial Agents and Chemotherapy 49:12, pages 5018-5023.
Crossref
Crossref
Minsheng Xia, Robert J. Suchland, Joli A. Carswell, John Van Duzer, Debra K. Buxton, Kara Brown, David M. Rothstein & Walter E. Stamm. (2005)
Activities of Rifamycin Derivatives against Wild-Type and
rpoB
Mutants of
Chlamydia trachomatis
. Antimicrobial Agents and Chemotherapy 49:9, pages 3974-3976.
Crossref
Crossref
Richard J. O'Brien & Mel Spigelman. (2005) New Drugs for Tuberculosis: Current Status and Future Prospects. Clinics in Chest Medicine 26:2, pages 327-340.
Crossref
Crossref
Andrei Kutlin, Stephan Kohlhoff, Patricia Roblin, Margaret R. Hammerschlag & Paul Riska. (2005)
Emergence of Resistance to Rifampin and Rifalazil in
Chlamydophila pneumoniae
and
Chlamydia trachomatis
. Antimicrobial Agents and Chemotherapy 49:3, pages 903-907.
Crossref
Crossref
Robert J. Suchland, Agnès Bourillon, Erick Denamur, Walter E. Stamm & David M. Rothstein. (2005)
Rifampin-Resistant RNA Polymerase Mutants of
Chlamydia trachomatis
Remain Susceptible to the Ansamycin Rifalazil
. Antimicrobial Agents and Chemotherapy 49:3, pages 1120-1126.
Crossref
Crossref
Mark S. Butler. (2005) Natural products to drugs: natural product derived compounds in clinical trials. Natural Product Reports 22:2, pages 162.
Crossref
Crossref
Clifton E. BarryIIIIII & Ken Duncan. (2004) Tuberculosis – strategies towards anti-infectives for a chronic disease. Drug Discovery Today: Therapeutic Strategies 1:4, pages 491-496.
Crossref
Crossref
Pauline M. Anton, Michael O'Brien, Efi Kokkotou, Barry Eisenstein, Arthur Michaelis, David Rothstein, Sophia Paraschos, Ciáran P. Kelly & Charalabos Pothoulakis. (2004)
Rifalazil Treats and Prevents Relapse of
Clostridium difficile
-Associated Diarrhea in Hamsters
. Antimicrobial Agents and Chemotherapy 48:10, pages 3975-3979.
Crossref
Crossref
Richard E. Chaisson. (2003) Treatment of Chronic Infections with Rifamycins: Is Resistance Likely To Follow?. Antimicrobial Agents and Chemotherapy 47:10, pages 3037-3039.
Crossref
Crossref